Banco Sabadell has led the first investment round of medtech company Thytech, which closed at €350,000. This marks the second investment from the fourth edition of the BStartup Health program, which received applications from 121 startups.

Thytech was founded by researchers from the Health Research Institute of Hospital Gregorio Marañón (IISGM) in Madrid and has developed a pioneering cell therapy aimed at preventing transplant rejection, according to a statement released by Banco Sabadell on Friday.

The investment is led by Banco Sabadell’s BStartup unit through its BStartup Health program, with participation from Genesis Biomed and private investors.

The innovation is based on the use of thyTreg cells, which have regulatory properties and are capable of controlling immune hyperactivation processes responsible for various serious and highly prevalent diseases.

Team leader Rafael Correa explained that although the results are still preliminary, “this strategy could open a new era in the treatment of many diseases associated with harmful inflammatory processes.”

Albert Figueras, Deputy General Manager of Banco Sabadell, stated that the funds raised will be used to continue developing the therapy, conduct regulatory studies, and follow the established roadmap “to bring this therapy to market and to patients.”

The therapy is currently focused on pediatric patients and “opens the door to reducing the use of immunosuppressive drugs” in these conditions, along with the side effects associated with their chronic use.

More info: bolsamania.com